Medications in Single-Dose Vials Implications of Discarded Drugs (2021) / Chapter Skim
Currently Skimming:
Appendix D: Biographical Information
Appendix D: Biographical Information
Pages 143-154
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 143... ...
He has served as the president and the chief executive officer of the American Medical Informatics Association, a professor in the School of Biomedical Informatics at the University of Texas Health Science Center in Houston, a professor of biomedical informatics at Arizona State University, a professor of basic medical sciences and a professor of medicine at the University of Arizona College of Medicine, and the founding dean of the Phoenix campus of the University of Arizona's College of Medicine.
|
From page 144... ...
Dr. Jena provided compensated expert litigation consulting services in 2020 and 2021 to pharmaceutical companies including Merck, Genentech, Sanofi-Aventis, Janssen, and others through his affiliation with Analysis Group.
|
From page 145... ...
, the SWOG Cancer Research Network, and the Eastern Cooperative Oncology Group. He has served on the Breast Cancer Screening and Diagnosis Panel and the Growth Factors Panel for the National Comprehensive Cancer Network and chairs clinical practice guidelines for the American Society of Clinical 1 Anupam Jena's biosketch has been updated since the release of this report to disclose compensated expert litigation consulting services to pharmaceutical companies during the course of the study and other consulting services to pharmaceutical companies before the start of the study.
|
From page 146... ...
Dr. Lyman made invited presentations in 2020 regarding the ASCO clinical practice guidelines for complications of cancer chemotherapy, the development of clinical pathways in oncology, and the work of the ASCO taskforce on biosimilars for which he received compensation from Jazz Pharmaceuticals, Merck Sharp & Dohme, Partner Therapeutics, Sandoz, and Seagen.
|
From page 147... ...
He was also an adjunct professor of internal medicine at the Yale University School of Medicine. Prior to joining Aetna, he served as the president and the chief executive officer of the Penn State Hershey Health System and as the senior vice president for health affairs at The Pennsylvania State University and the dean of its College of Medicine for 8 years.
|
From page 148... ...
She is the associate editor of the Journal of the National Cancer Institute and is on the editorial boards of Value in Health, PharmacoEconomics, and JCO: Oncology Practice. She is a member of the American Cancer Society guidelines development workgroup and was a member of the National Cancer Policy Forum at the National Academies of Sciences, Engineer ing, and Medicine.
|
From page 149... ...
He was the inaugural recipient of the University of Washington/Allergan Global Health Economics and Outcomes Research Fellowship. He serves the California state legislature as a faculty content expert for the California Health Benefits Review Program and was a member of the advisory group on pain assessment and management standards for long-term care organizations for The Joint Commission.
|
From page 150... ...
He has served as a professor of medicine and pharmacology at Weill Cornell Medical College in New York and has served on a number of editorial boards. He was a member of the New England Journal of Medicine editorial board, served as the drug therapy editor of the New England Journal of Medicine, and was on the editorial board of the British Journal of Clinical Pharmacology and The Scientist.
|
From page 151... ...
clinical practice guidelines for complications of cancer chemotherapy, the development of clinical pathways in oncology, and the work of the ASCO taskforce on biosimilars for which he received compensation from Jazz Pharmaceuticals, Merck Sharp & Dohme, Partner Therapeutics, Sandoz, and Seagen. Although the topics of these presentations were not directly related to the specific questions addressed by the committee, because the recommendations of the study could be viewed as having a direct impact on the financial interests of some of these companies, the National Academies have concluded that Dr.
|
From page 152... ...
Andrada, M.A., is an associate program officer in the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine, working on the consensus study on the implication of discarded weight-based drugs. Prior to joining the National Academies, she served as a lead research scientist supporting the Defense Health Board and the Defense Health Agency by producing technical reports on various public health topics affecting the military, such as child abuse and neglect and low-volume, high-risk surgical procedures throughout the Military Health System.
|
From page 153... ...
Sharyl J Nass, Ph.D., serves as the senior director of the Board on Health Care Services and the director of the National Cancer Policy Forum at the National Academies of Sciences, Engineering, and Medicine.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.